Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid
Avadel climbs as Lundbeck outbids Alkermes in latest bidding war
Avadel settles with Jazz Pharma; agrees to be acquired by Alkermes
Alkermes, DaVita, Jabil, Ralph Lauren, among potential M&A candidates - BofA
Alkermes falls as activist holder Sarissa Capital cuts stake
5.69BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
USG017671052
CUSIP
01642T108
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
23.57
PEG Ratio
1.96
Book Value
10.99
Dividend Share
-
Dividend Yield
-
Earnings Share
1.43
Wall Street Target Price
44.24
EPS Estimate Current Year
0.06
EPS Estimate Next Year
0.70
EPS Estimate Current Quarter
0.4481
EPS Estimate Next Quarter
0.2667
Most Recent Quarter
-
Revenue TTM
1,475,899,008
Gross Profit TTM
1,279,442,048
EBITDA
281,120,992
Profit Margin
16.37%
Return On Assets TTM
6.99%
Return On Equity TTM
14.72%
Revenue Per Share TTM
8.961
Qtly Revenue Growth YOY
-10.60%
Diluted Eps TTM
1.43
Qtly Earnings Growth YOY
-67.00%
Trailing PE
23.57
Forward PE
149
Price Sales TTM
3.8063
Price Book MRQ
3.1198
Enterprise Value Revenue
3
Enterprise Value EBITDA
15
16.68
2.30%114.70
0.73%40.21
0.30%29.19
0.00%33.20
0.00%201.00
-4.66%128.12
-4.29%25.13
-3.66%35.05
-0.99%9.24
-0.76%